Contact Us
Drug Search Results
More Filters [+]

Meprobamate

Alternative Names: meprobamate, diurnal, proquanil, amosene, equanil, meprospan, bamate, miltown, tranmep, neuramate, mepriam, equagesic, milprem-400, milprem-200, pmb 400, micrainin, pmb 200, q-gesic
Latest Update: 2024-09-23
Latest Update Note: News Article

Product Description

Meprobamate is used to treat anxiety disorders or for short-term relief of the symptoms of anxiety in adults and children 6 years of age and older. Meprobamate is in a class of medications called tranquilizers. It works by slowing activity in the brain to allow for relaxation. (Sourced from: https://medlineplus.gov/druginfo/meds/a682077.html)

Mechanisms of Action: GABA Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous,Intraocular

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Brazil | Canada | Chile | Egypt | Ireland | Lebanon | Morocco | New Zealand | Pakistan | Portugal | South Africa | Taiwan | Thailand | Tunisia | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Meprobamate

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

09/23/2024

News Article

 Addison's Disease Therapeutics Market to Grow by USD 442.4 Million (2024-2028) as Special Drug Designations Drive Growth, with AI Redefining the Market Landscape - Technavio

09/09/2024

News Article

 Drut Technologies Delivers Virtual Disaggregation for GPU Servers

07/30/2024

News Article

 NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs)

07/30/2024

News Article

 NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs)

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions